Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
Reported Friday, Neurocrine Biosciences' CRENESSITY Receives FDA Approval, Revolutionizing Treatment For Classic Congenital Adrenal Hyperplasia
週五報告，神經分泌生物科學的CRENESSITY獲得FDA批准，徹底改變經典先天性腎上腺增生的治療。
- CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach
- FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week
Rare Pediatric Disease Priority Review Voucher granted in connection with approval
- FDA approval supported by data from the largest-ever clinical trial program in pediatric and adult patients with classic CAHCRENESSITY is expected to be commercially available in approximately one week
- CRENESSITY是經典先天性腎上腺皮質增生（CAH）社區70年來可用的第一種新療法，它提供了一種改變模式的治療方法
- 在有史以來規模最大的針對兒科和成人患者的經典CAHCRENESSITY臨床試驗項目的數據的支持下，美國食品藥品管理局的批准預計將在大約一週內上市
與批准相關的罕見兒科疾病優先審查憑證
- 在有史以來規模最大的針對兒科和成人患者的經典CAHCRENESSITY臨床試驗項目的數據的支持下，美國食品藥品管理局的批准預計將在大約一週內上市